retatrutide lilly Lilly's Retatrutide: Toward the End of Incremental Metabolic Medicine The biggest retatrutide headline may

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes

As these drugs became more widely used, some patients began reporting serious side effects, including severe stomach and digestive problems

Surgical interventions In cases where non-surgical methods are not sufficient, surgical interventions such as plastic surgery may be considered

doi: 10.1161/CIRCULATIONAHA.111.039453 114 BrayGAChatellierADuncanCGreenwayFLLevyERyanDHet al

Saxenda contains the active ingredient liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist

Keep reading to learn more and visit the October Quarterly Drug Pipeline for more clinical insights on anticipated drugs in development